Hannam & Partners, a leading independent investment bank, issued an independent research report on Psyence Group.

The report identifies the company as a first mover into the palliative care market supported by natural psilocybin production.

It notes that while Psyence has already generated revenue through its functional mushroom joint venture (Psyence Function) and production facility vertical (Psyence Production), it attributes the lion’s share of Psyence’s value to its drug discovery programme and expects a 450 per cent uplift in share price.

Psyence Group Inc. (PSYG) opened trading at C$0.10

More From The Market Online

@ the Bell: Could the TSX keep hold of recent gains?

The biggest drag on the TSX was sustained by the heavyweight energy and mining sectors, while industrials and utilities also fell.
Mandalay Resources - Mandalay's Björkdal gold mine in Sweden.

This profitable gold stock is on its way up

An attractive stock to consider under a gold-equity dislocation thesis is Mandalay Resources, whose mines are profitable and 100%-owned.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.